NetRegulus, Inc Announces Innovative Quality Complaints Solution for Life Sciences Companies
Posted on: Monday, 12 December 2005, 09:00 CST
CENTENNIAL, Colo., Dec. 12 /PRNewswire/ -- NetRegulus(R), Inc, an established provider of Enterprise Compliance Software for Regulated Industries, announces the availability of its newest offering, Complaints, within its Quality Application Suite of Products. This product is the latest in a series of modules being delivered as a part of the innovative NetRegulus NetRM(TM) Software Solution announced October 17, 2005. The NetRegulus NetRM Enterprise Quality and Study Solutions are web-based and represent a leap forward in regulatory data management due to their unique common data model and integrated modular application architecture. The system is designed for shortened time-to-value, reduced total cost of ownership, configurability by the end user, and scalability.
Building on over 7 years of experience delivering quality solutions to Life Sciences companies, NetRegulus NetRM Complaints provides a highly configurable comprehensive data management tool for all activities associated with complaint handling in a regulated environment. Complaints enables the user to manage the investigation, resolution and regulatory reporting of customer complaints including the tracking of relevant product and customer information.
"The release of NetRegulus NetRM Complaints is further proof of NetRegulus' commitment to deliver leading edge regulatory compliance solutions designed specifically for Life Sciences companies", said Dave Siebert, President and CEO of NetRegulus. "Leveraging our significant domain expertise and input from our customers, we have delivered a comprehensive data management product that meets our customer's needs and positions us in a leadership role within our industry."
Leveraging the powerful NetRegulus NetRM underlying framework, Complaints customers have access to workflow and alerts capabilities that can be configured to support their specific processes, decision tree elements for regulatory reporting decisions and risk assessments, fully integrated reporting and ad hoc query capabilities, and language localization or multi-lingual support. Customers can associate multiple products, manufacturing sites, vendors or classifications to each complaint and can manage activities, cancel or reassign actions and change due dates as required. The Complaints solution also has enhanced MedWatch Baseline and Alternative Summary Reporting and standard Canadian regulatory and Vigilance reporting.
About NetRegulus, Inc.
Located in Denver, CO, NetRegulus is a provider of web-based Enterprise Regulatory Management software that allows Life Science companies to effectively manage their clinical study and quality data. Our products allow organizations to manage complex data requirements from clinical trials through regulated post market activities within a single integrated and modular system. Our products are developed to help Life Science companies meet ever increasing global regulatory requirements and to improve operational efficiencies, launch products to market faster and proactively identify potential product quality problems.
For additional information, contact: Joel Reed -- Vice President of Marketing joel.reed@netregulus.com 888-707-6900
NetRegulus, Inc
CONTACT: Joel Reed, Vice President of Marketing of NetRegulus, Inc,+1-888-707-6900, joel.reed@netregulus.com
Source: PRNewswire
Related Articles
- Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples
- Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
- New Data Show Treatment of Multiple Sclerosis (MS) With AVONEX(R) (Interferon Beta-1a) Enhances Quality of Life
- Excipients Help Pharma Extend Product Life, Profits
- Nortel Launches Data Products for Growing Enterprises
- Amerex Data Products Now Available Through DTN's ProphetX Platform
- Report: Quality-of-Life Principles for MS
- Longitudinal Study of Quality of Life in Patients With Localized Prostate Cancer Undergoing Radiotherapy
- New Data Demonstrate Alvesco(R) (Ciclesonide) Significantly Improves Quality-of-Life for Patients With Mild-to-Moderate Asthma
- New Phase II Data Shows Improvement in Disease Activity and Quality of Life for Psoriasis Patients With Abbott's HUMIRA(R) (Adalimumab)
User Comments (0)

RSS Feeds